Response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial

BACKGROUND: Consensus is lacking regarding the optimal salvage therapy for patients with follicular lymphoma who relapse after or are refractory to immunochemotherapy. METHODS: This phase II trial evaluated the efficacy and safety of response‐adapted therapy with rituximab, bendamustine, mitoxantron...

Descripción completa

Detalles Bibliográficos
Autores principales: Peñalver, Francisco‐Javier, Márquez, José‐Antonio, Durán, Soledad, Giraldo, Pilar, Martín, Alejandro, Montalbán, Carlos, Sancho, Juan‐Manuel, Ramírez, María‐José, Terol, María‐José, Capote, Francisco‐Javier, Gutiérrez, Antonio, Sánchez, Blanca, López, Andrés, Salar, Antonio, Rodríguez‐Caravaca, Gil, Canales, Miguel, Caballero, María‐Dolores
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853826/
https://www.ncbi.nlm.nih.gov/pubmed/31573746
http://dx.doi.org/10.1002/cam4.2555

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853826/
https://www.ncbi.nlm.nih.gov/pubmed/31573746
http://dx.doi.org/10.1002/cam4.2555

Ejemplares similares